Pfiz­er takes aim at a flag­ship fran­chise at Sanofi and Re­gen­eron — and scores a few di­rect hits

Count Pfiz­er in as a top play­er in the block­buster game of JAK1 in­hibitors.

Over the week­end the phar­ma gi­ant post­ed some stel­lar Phase III ef­fi­ca­cy da­ta for their heavy­weight con­tender abroc­i­tinib in atopic der­mati­tis (eczema) that lines up ahead of a boom­ing Dupix­ent (dupilum­ab), a block­buster in the port­fo­lios of Re­gen­eron and Sanofi. And they put some re­al dis­tance ahead of Eli Lil­ly’s trail­ing Olu­mi­ant, which made a de­layed ini­tial ar­rival on the mar­ket for rheuma­toid arthri­tis af­ter the FDA hob­bled it with some ad­di­tion­al hur­dles on safe­ty con­cerns.

JADE-MONO-1 scores well for Pfiz­er, tee­ing up what will be an in­tense­ly fol­lowed break­down of the JADE MONO-2 da­ta, which the phar­ma gi­ant re­cent­ly top-lined as “sim­i­lar” to the first Phase III when test­ed against a place­bo — a con­trol group that has been eas­i­ly out­classed by all the drugs in this mar­ket niche.

As of now, Pfiz­er looks to be equipped to run in­to the re­view stage — ad­van­taged by a break­through ther­a­py des­ig­na­tion that is in­tend­ed to speed up the reg­u­la­to­ry process.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER